Skip to content

Opening book details…

Can I read Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage—Preparation, in vitro screening and molecular docking on EtoBox?

Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage—Preparation, in vitro screening and molecular docking by Kamil Musilek; Marketa Komloova; Ondrej Holas; Anna Horova; Miroslav Pohanka; Frank Gunn-Moore; Vlastimil Dohnal; Martin Dolezal; Kamil Kuca is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage—Preparation, in vitro screening and molecular docking about?

The treatment of organophosphorus (OP) poisoning consists of the administration of a parasympatholytic agent (e.g., atropine), an anticonvulsant (e.g., diazepam) and an acetylcholinesterase (AChE) reactivator (e.g., obidoxime). The AChE reactivator is the causal treatment of OP exposure, because it cleaves the OP moiety covalently bound to the AChE active site. In this paper, fourteen novel AChE reactivators are described. Their design originated from a former promising compound K027. These compounds were synthesized, evaluated in vitro on human AChE (hAChE) inhibited by tabun, paraoxon, methylparaoxon and DFP and then compared to commercial hAChE reactivators (pralidoxime, HI-6, trimedoxime, obidoxime, methoxime) or previously prepared compounds (K027, K203). Three of these novel compounds showed a promising ability to reactivate hAChE comparable or better than the used standards. Consequently, a molecular docking study was performed for three of these promising novel compounds. The docking results confirmed the apparent influence of π-π or cation-π interactions and hydrogen bonding for reactivator binding within the hAChE active site cleft. The SAR features concerning the non-oxi

Who reads Mono-oxime bisquaternary acetylcholinesterase reactivators with prop-1,3-diyl linkage—Preparation, in vitro screening and molecular docking?

It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.

Author
Kamil Musilek; Marketa Komloova; Ondrej Holas; Anna Horova; Miroslav Pohanka; Frank Gunn-Moore; Vlastimil Dohnal; Martin Dolezal; Kamil Kuca
Publisher
Elsevier Science; Elsevier ; Elsevier Ltd.; Elsevier BV (ISSN 0968-0896)
Published
2011
Language
EN
Field
Biochemistry, Genetics and Molecular Biology (Life Sciences)

More by Kamil Musilek; Marketa Komloova; Ondrej Holas; Anna Horova; Miroslav Pohanka; Frank Gunn-Moore; Vlastimil Dohnal; Martin Dolezal; Kamil Kuca

Browse all works by Kamil Musilek; Marketa Komloova; Ondrej Holas; Anna Horova; Miroslav Pohanka; Frank Gunn-Moore; Vlastimil Dohnal; Martin Dolezal; Kamil Kuca